Since the US Food and Drug Administration (FDA) endorsed the use of in vitro preclinical studies to expand CFTR modulator labeling for the treatment of CF in 2017, many rare CFTR variants have been suggested or approved for CFTR modulator treatment through therapying studies [2,3,4,5]. The gene discussed is CFTR; the disease is cystic fibrosis.